CN107073069B - 作为人免疫蛋白酶体的抑制剂的二肽模拟物 - Google Patents

作为人免疫蛋白酶体的抑制剂的二肽模拟物 Download PDF

Info

Publication number
CN107073069B
CN107073069B CN201580056519.4A CN201580056519A CN107073069B CN 107073069 B CN107073069 B CN 107073069B CN 201580056519 A CN201580056519 A CN 201580056519A CN 107073069 B CN107073069 B CN 107073069B
Authority
CN
China
Prior art keywords
formula
compound
alkyl
nmr
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580056519.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107073069A (zh
Inventor
林钢
C·纳桑
P·K·辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Priority to CN202210151955.1A priority Critical patent/CN114796207A/zh
Publication of CN107073069A publication Critical patent/CN107073069A/zh
Application granted granted Critical
Publication of CN107073069B publication Critical patent/CN107073069B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/14—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
CN201580056519.4A 2014-08-18 2015-08-12 作为人免疫蛋白酶体的抑制剂的二肽模拟物 Active CN107073069B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210151955.1A CN114796207A (zh) 2014-08-18 2015-08-12 作为人免疫蛋白酶体的抑制剂的二肽模拟物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462038636P 2014-08-18 2014-08-18
US62/038,636 2014-08-18
PCT/US2015/044876 WO2016028571A2 (en) 2014-08-18 2015-08-12 Dipeptidomimetics as inhibitors of human immunoproteasomes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210151955.1A Division CN114796207A (zh) 2014-08-18 2015-08-12 作为人免疫蛋白酶体的抑制剂的二肽模拟物

Publications (2)

Publication Number Publication Date
CN107073069A CN107073069A (zh) 2017-08-18
CN107073069B true CN107073069B (zh) 2022-03-08

Family

ID=55351371

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580056519.4A Active CN107073069B (zh) 2014-08-18 2015-08-12 作为人免疫蛋白酶体的抑制剂的二肽模拟物
CN202210151955.1A Pending CN114796207A (zh) 2014-08-18 2015-08-12 作为人免疫蛋白酶体的抑制剂的二肽模拟物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210151955.1A Pending CN114796207A (zh) 2014-08-18 2015-08-12 作为人免疫蛋白酶体的抑制剂的二肽模拟物

Country Status (5)

Country Link
US (3) US11202817B2 (enExample)
EP (1) EP3193904B1 (enExample)
JP (1) JP6758282B2 (enExample)
CN (2) CN107073069B (enExample)
WO (1) WO2016028571A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2748434T3 (es) 2014-01-10 2020-03-16 Univ Cornell Dipéptidos como inhibidores de inmunoproteasomas humanos
US11202817B2 (en) * 2014-08-18 2021-12-21 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
EP4006012A1 (en) 2015-10-15 2022-06-01 Cornell University Proteasome inhibitors and uses thereof
WO2019075252A1 (en) 2017-10-11 2019-04-18 Cornell University PEPTIDOMIMETIC INHIBITORS OF PROTEASOME

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1809570A (zh) * 2003-06-03 2006-07-26 日本化药株式会社 [1,2,4]三唑并[1,5－a]嘧啶－2－基脲衍生物及其用途
JP2014091731A (ja) * 2012-11-06 2014-05-19 Kobe Gakuin 新規ソマトスタチン由来ペプチド化合物並びに該化合物を含むｄｎａポリメラーゼ阻害剤、抗癌剤及びアポトーシス誘導剤。

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW223629B (enExample) 1992-03-06 1994-05-11 Hoffmann La Roche
US7001921B1 (en) 1995-01-23 2006-02-21 Biogen Idec Ma Inc. Cell adhesion inhibitors
AR011515A1 (es) 1996-12-25 2000-08-30 Agrogene Ltd Derivado del acido aminobutirico para la proteccion de plantas de enfermedades fungosas y un metodo para proteger un cultivo contra enfermedadesfungosas por ejemplo tomates y papas contra el tizon tardio o temprano, cereales contra el mildiu polvoroso, y pepino, vides, melones contra el mildiu
CA2423868C (en) 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
US7244743B2 (en) 2002-06-05 2007-07-17 Solvay Pharmaceuticals Gmbh Non-peptidic BRS-3 agonists
AU2003262642B2 (en) * 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
CN100367949C (zh) 2002-09-13 2008-02-13 有限会社绪方研究 黑色素消除制剂
AR050258A1 (es) 2004-07-21 2006-10-11 Mitsui Chemicals Inc Derivado de diamina, proceso de la preparacion de este, y fungicida que contiene el derivado de diamina como ingrediente activo
TW200621223A (en) 2004-09-07 2006-07-01 Smithkline Beecham Corp Acyclic 1,3-diamines and uses therefor
WO2006065826A2 (en) * 2004-12-15 2006-06-22 Merck & Co., Inc. Process to chiral beta amino acid derivatives by asymmetric hydrogenation
US7589066B2 (en) 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
JP2006298785A (ja) 2005-04-18 2006-11-02 Mitsui Chemicals Inc ジアミン誘導体、その製造方法およびそれらを有効成分とする殺菌剤
US20090227601A1 (en) 2005-12-07 2009-09-10 Amgen Inc. Bradykinin 1 Receptor Antagonists
WO2007083394A1 (ja) 2006-01-19 2007-07-26 Mitsui Chemicals, Inc. ジアミン誘導体を含む有害生物防除組成物
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
DE102007025718A1 (de) * 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
US8183235B2 (en) 2007-09-11 2012-05-22 Tokyo University Of Science Educational Foundation Administrative Organization Dihydronaphthalene compound and use thereof
EP2212334B1 (en) 2007-10-16 2012-08-15 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
EP2487152A1 (en) 2010-11-17 2012-08-15 UCB Pharma GmbH Process for the preparation of Lacosamide including resolution of O-methyl-DL-serine
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
EP2949344A3 (en) 2011-03-18 2016-01-13 Catabasis Pharmaceuticals, Inc. Use of intracellular enzymes for the release of covalently linked bioactives
CN102807601B (zh) 2011-06-03 2014-02-26 首都医科大学 氨基酰-色氨酰-5-甲氧色胺及其制备方法和应用
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
SG10201605152SA (en) 2011-12-22 2016-08-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
NZ708175A (en) 2012-12-21 2020-06-26 Hoffmann La Roche Peptides as oxytocin agonists
WO2015076359A1 (ja) 2013-11-21 2015-05-28 国立大学法人北海道大学 プロテアソーム阻害性化合物
ES2748434T3 (es) 2014-01-10 2020-03-16 Univ Cornell Dipéptidos como inhibidores de inmunoproteasomas humanos
US11202817B2 (en) * 2014-08-18 2021-12-21 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
EP4006012A1 (en) 2015-10-15 2022-06-01 Cornell University Proteasome inhibitors and uses thereof
WO2019075252A1 (en) 2017-10-11 2019-04-18 Cornell University PEPTIDOMIMETIC INHIBITORS OF PROTEASOME

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1809570A (zh) * 2003-06-03 2006-07-26 日本化药株式会社 [1,2,4]三唑并[1,5－a]嘧啶－2－基脲衍生物及其用途
JP2014091731A (ja) * 2012-11-06 2014-05-19 Kobe Gakuin 新規ソマトスタチン由来ペプチド化合物並びに該化合物を含むｄｎａポリメラーゼ阻害剤、抗癌剤及びアポトーシス誘導剤。

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
Defining the Mechanism of Action and Enzymatic Selectivity of Psammaplin A against Its EpigeneticTargets;Baud, Matthias G. J.; Leiser, Thomas; Haus, Patricia; 等;《JOURNAL OF MEDICINAL CHEMISTRY》;20120223;第55卷(第4期);第1735页 *
DUKE, SS ; BOOTS,MR.6. SYNTHESIS AND BIOLOGICAL EVALUATION OF SPARSOMYCIN ANALOGS.《JOURNAL OF MEDICINAL CHEMISTRY》.1983,第26卷(第11期),第1556-1561页. *
RN 120655-16-5;REGISTRY;《STN Columbus》;19890512;第1页 *
RN 1461869-28-2;REGISTRY;《STN Columbus》;20131021;第1页 *
RN 294889-15-9;REGISTRY;《STN Columbus》;20001012;第1页 *
RN 3641-55-2;REGISTRY;《STN Columbus》;19841116;第1页 *
RN 50633-04-0;REGISTRY;《STN Columbus》;19841116;第1页 *
RN 51219-69-3;REGISTRY;《STN Columbus》;19841116;第1页 *
RN 51219-75-1;REGISTRY;《STN Columbus》;19841116;第1页 *
RN 59973-55-6;REGISTRY;《STN Columbus》;19841116;第1页 *
RN 839730-13-1;REGISTRY;《STN Columbus》;20050501;第1页 *
RN 839730-21-1;REGISTRY;《STN Columbus》;20050501;第1页 *
RN 839730-22-2;REGISTRY;《STN Columbus》;20050501;第1页 *
RN 866779-17-1;REGISTRY;《STN Columbus》;20051104;第1页 *
RN 87639-77-8;REGISTRY;《STN Columbus》;19841116;第1页 *

Also Published As

Publication number Publication date
CN114796207A (zh) 2022-07-29
EP3193904B1 (en) 2025-10-01
WO2016028571A3 (en) 2016-09-29
US12016896B2 (en) 2024-06-25
US20180221431A1 (en) 2018-08-09
US11202817B2 (en) 2021-12-21
JP6758282B2 (ja) 2020-09-23
US20220080022A1 (en) 2022-03-17
EP3193904A4 (en) 2018-04-11
EP3193904A2 (en) 2017-07-26
CN107073069A (zh) 2017-08-18
WO2016028571A2 (en) 2016-02-25
JP2017530947A (ja) 2017-10-19
US20250114428A1 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
US12016896B2 (en) Dipeptidomimetics as inhibitors of human immunoproteasomes
JP6634519B2 (ja) 置換トリアゾロピペラジン類ｐａｒｐ抑制剤及びその製造方法並びに用途
KR101596524B1 (ko) 항바이러스 화합물
CA2525502C (en) Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
US9988421B2 (en) Dipeptides as inhibitors of human immunoproteasomes
TW202344252A (zh) 一種喜樹鹼衍生物，基於其的抗體－藥物偶聯物和藥物組成物，及其應用
CN108351169B (zh) 蛋白酶体抑制剂及其用途
CN113614095B (zh) 作为精氨酸酶抑制剂的烷基硼酸类化合物
CN113710687A (zh) 环肽抗生素
US9782392B2 (en) Azaindole derivative
CA2989989C (en) Pyrrolo[2,3-d]pyrimidine compound or salt thereof
US9469656B2 (en) HDAC inhibitors as anti-cancer agents
HK40094002A (en) Aminocarbamoyl compounds for the treatment of viral infections
HK40004704A (en) Cyclic peptides as c5 a receptor antagonists
WO2015158306A1 (zh) 一类乙二醛酶i不可逆抑制剂及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant